Karyopharm Announces FDA Approval of XPOVIO® (selinexor) for the Treatment of Patients with Relapsed or Refractory
Karyopharm Therapeutics Angeforderte Firma
Karyopharm is an innovation-driven pharmaceutical company whose core technology leverages the inhibition of nuclear export as a mechanism to treat patients with cancer and other medical conditions Weiterlesen
There is a lack of transparency in GMSA and it creates a competitive environment. While I have full trust in the executive team, I do not trust my GMSA leadership team. I recommend this survey is sent to all employees as many others may agree. I recommend investing in a program to retain talent
Was sind einige der besten Dinge an Ihrem Team?
Almost everyone on my team has strong work ethic and is collaborative.
Was macht Sie bei der Arbeit am glücklichsten?
The potential to make an impact in patients and on the business
Was ist am positivsten an Kultur und Umgang in Ihrem Unternehmen?
High performers are rewarded as they should be. People are recognized for their hard work and effort. Nothing gets done with an n of one. We are all achieving greatness together.
Was ist das Beste an Ihrem Vergütungspaket?
I am compensated well however I am working harder than I ever have and I don’t feel that I am compensated at that level. I have done this same role at prior companies and been compensated the same
Was gefällt dir am besten am Führungsteam?
The executive team has a perfect balance of being committed to furthering the science and helping patients while understanding what it means to run a business. What Karyopharm has accomplished in the past decade is truly impressive and that speaks to diligence and commitment of this leadership team.
Other Employee Reviews for Karyopharm Therapeutics
×